July 11-12, 2011 | Millbrae, California

ABOUT THE CONFERENCE

While there is much discussion and hype surrounding the value and importance of furthering the integration of personalized medicine within healthcare systems throughout the world, in order to realize the dream and vision of personalized medicine, diagnostic tests must be fully partnered with these new and unique therapies. Creating strong partnerships with pharmaceutical and biotechnology corporations in order to develop tests in tandem with therapy development has long been a challenge for diagnostic corporations, who face a much different set of challenges in bringing their products to market.

From funding to reimbursement considerations, diagnostic companies are taking much greater risks in developing companion diagnostic tests, something that is often lost on larger pharmaceutical corporations. Unlike many of the personalized medicine conferences currently available, the Q1 conference will continue to focus on the perspective of the diagnostic company; with topics focused on challenges across the board; from attracting partners, contracting and IP considerations, to sessions focused on case studies of companies that have successfully partnered with pharmaceutical companies throughout the lifecycle of personalized medicines. With a well rounded speaker roster including diagnostic, pharmaceutical and biotechnology companies, this program will encompass the entire vision of personalized medicine, bringing it to life.

TOPICS TO BE COVERED

• Realizing the Vision of Personalized Medicine
  
• Companion Tests from a Pharmaceutical Perspective
• Communication Strategies for Finding and Attracting Partners for Companion Diagnostics
  
• Engaging Pharmaceutical Companies in Partnerships
  
• Companion Diagnostics: Necessary Evolution of Medicine
  
• Panel Discussion: Pharmaceutical Expectations in Forming Successful Partnerships
  
• Reconciling Economic Differences when Partnering to Develop Companion Diagnostics
  
• Achievable Timelines for Companion Test Development
  
• Enablement of Personalized Medicine Through Partnerships with Academic Medical Centers
  
• IP & Patent Protection in Partnership Negotiations
  
• Success in Early-Stage Partnership in Personalized Medicine
  
• Biomarker Identification & Marketing to Potential Partners
  
• Getting Paid for Drug-Diagnostic Companion Products
  
• Panel Discussion: Regulatory Perspectives on Clearance Routes for Companion Tests
  
• Panel Discussion: Novel Biomarkers in Early Detection and Management of Diabetes
  
• Role of Companion Diagnostics in Diabetes Drug Development
  
• Bringing Value-based Diagnostics to Market: Changing the Drug-Diagnostic Value Paradigm
  
• Consumers, Genomes & Research: The Power of Numbers for the Future of Personalized Medicine
  
• Strategies of Marketing Companion Diagnostic Tests Directly to Physicians

Conference Venue/Hotel
Westin San Francisco Airport
1 Old Bayshore Highway
Millbrae, CA 94030

View Larger Map

PRESENTERS TO INCLUDE

Pierre Cassigneul
CEO & President, XDx
Board Member
Personalized Medicine Coalition

George Maliekal
Senior Director, Business Development
Abbott Molecular

Michael Penn, MD, PhD
Senior Manager of Business Development
Genentech

Dr. David Jackson
Sr. Director, Companion Diagnostic Partnerships
QIAGEN

And More...

To request the full two-day conference agenda, information on promotional pricing & registration details please contact:
Paul Hernandez
Marketing Director
phernandez@Q1productions.com
P: 312.602.9683

F: 312.873.3969